- NanoString Technologies (NSTG +41%) soars after receiving FDA 510(k) clearance for its Prosigna diagnostic test.
- The test uses the gene expression profile of cells found in breast cancer tissue to assess a patient's risk of distant recurrence of disease.
- Prosigna is the company's first FDA-approved in vitro diagnostic assay, and CEO Brad Gray notes the approval "marks a milestone for NanoString and is an important step forward in the treatment of breast cancer."
NanoString Technologies Introduces nCounter Elements(TM) Reagents to Support Needs of Translational Research and Clinical Laboratory Testing
at CNBC.com (Jul 29, 2013)